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Objectives The purpose of this study was to assess whether transradial access for ST-segment elevation acute coronary syn-
drome undergoing early invasive treatment is associated with better outcome compared with conventional trans-
femoral access.
Background In patients with acute coronary syndrome, bleeding is a significant predictor of worse outcome. Access site com-
plications represent a significant source of bleeding for those patients undergoing revascularization, especially
when femoral access is used.
Methods The RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome)
was a multicenter, randomized, parallel-group study. Between January 2009 and July 2011, 1,001 acute
ST-segment elevation acute coronary syndrome patients undergoing primary/rescue percutaneous coronary in-
tervention were randomized to the radial (500) or femoral (501) approach at 4 high-volume centers. The primary
endpoint was the 30-day rate of net adverse clinical events (NACEs), defined as a composite of cardiac death,
stroke, myocardial infarction, target lesion revascularization, and bleeding). Individual components of NACEs and
length of hospital stay were secondary endpoints.
Results The primary endpoint of 30-day NACEs occurred in 68 patients (13.6%) in the radial arm and 105 patients
(21.0%) in the femoral arm (p  0.003). In particular, compared with femoral, radial access was associated with
significantly lower rates of cardiac mortality (5.2% vs. 9.2%, p  0.020), bleeding (7.8% vs. 12.2%, p  0.026),
and shorter hospital stay (5 days first to third quartile range, 4 to 7 days] vs. 6 [range, 5 to 8 days]; p  0.03).
Conclusions Radial access in patients with ST-segment elevation acute coronary syndrome is associated with significant clini-
cal benefits, in terms of both lower morbidity and cardiac mortality. Thus, it should become the recommended
approach in these patients, provided adequate operator and center expertise is present. (Radial Versus Femoral
Investigation in ST Elevation Acute Coronary Syndrome [RIFLE-STEACS]; NCT01420614) (J Am Coll Cardiol
2012;60:2481–9) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.06.017Bleeding complications in patients with acute coronary
syndrome are a significant predictor of morbidity and
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accepted June 19, 2012.mortality (1–3). In particular, patients with ST-segment
elevation acute coronary syndrome (STEACS) constitute a
high-risk subset of acute patients requiring more aggressive
pharmacological treatment (e.g., glycoprotein IIb/IIIa in-
See page 2500
hibitors, thrombolysis) and urgent revascularization strategy
(4,5). In these patients, access site complications still rep-
resent a significant source of bleeding, especially when
femoral access is used (6,7).
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ment of new more selective and
safe antithrombotic agents, the use
of radial access remains likely the
best way to dramatically affect
access site–related bleeding risk
(7–12). Indeed, although techni-
cally more demanding, the trans-
radial approach has been demon-
strated feasible in the acute
coronary syndrome setting and the
safest in terms of local vascular
complications (13–17).
Whether this evident access-site bleeding reduction may
also have a positive impact on prevention of further cardiovas-
cular events remains to be defined. The available clinical
evidence summarized in a recent meta-analysis seems to
suggest that the radial approach could also be associated with
improved outcome (12). Moreover, the RIVAL (Radial Versus
Femoral Access for Coronary Intervention) trial showed a clear
benefit in terms of mortality in the subgroup of patients with
STEACS undergoing percutaneous coronary intervention
(PCI) (18). Nonetheless, the small sample size of conducted
randomized trials, all underpowered to detect difference for
hard clinical event (e.g., death), and the inevitable selection bias
of observational studies included in the meta-analysis prevent
any conclusion.
In this trial, we aimed to test, in an adequately powered
study, whether transradial access for STEACS treatment
was associated with better outcomes compared with the
conventional transfemoral approach.
Methods
Study design and endpoints. The RIFLE-STEACS (Ra-
dial Versus Femoral Randomized Investigation in ST-
Elevation Acute Coronary Syndrome) was a multicenter,
randomized, parallel-group, investigator-initiated study. All
patients with suspected STEACS planned for early revas-
cularization strategy (within 24-h of symptom onset) were
eligible for the study. Before arterial stick for percutaneous
access, all enrolled patients were randomized (1:1 ratio) to
radial or femoral access according to opaque, numbered,
sealed envelopes with randomization based on a computer-
generated random series and stratified by center. By proto-
col, contraindication to either radial or femoral vascular
access (e.g., abnormal Allen’s test or known severe periph-
eral vascular disease), recent stroke (within 4 weeks), anti-
coagulant therapy assumption with an international normal-
ized ratio 2, or other severe bleeding diathesis were the
pre-specified exclusion criteria adopted, whereas presenta-
tion with cardiogenic shock and/or hemodynamic instability
did not preclude enrollment. The study protocol received
ethical committee approval, and written informed consent
Abbreviations
and Acronyms
CI  confidence interval
HR  hazard ratio
NACE  net adverse
clinical event
PCI  percutaneous
coronary intervention
STEACS  ST-segment
elevation acute coronary
syndromewas obtained by the patient or immediate family member incase the patient’s clinical condition precluded the ability to
provide written consent.
As the primary endpoint of the study, we assessed the
30-day incidence of net adverse clinical events (NACEs),
defined as the composite of cardiac death, myocardial
infarction, stroke, target lesion revascularization, and non–
coronary artery bypass graft–related bleeding. Secondary
endpoints were 30-day individual components of NACEs
and hospital stay. Endpoint adjudication was performed by
a blinded central independent clinical-event committee.
Patients and investigators were not blinded to the proce-
dure. No extramural funding was used to support this work,
and authors are solely responsible for the design, conduct,
and final contents of this study.
Population and procedures. The study population in-
cluded patients undergoing primary/rescue PCI at 4 high-
volume centers. Procedural anticoagulation was achieved
with preliminary administration of an unfractionated hep-
arin bolus at a dose of 70 UI/kg, supplemented during the
procedure to maintain an activated clotting time of 250 s.
The choice of additional periprocedural antithrombotic
agents (e.g., glycoprotein IIb/IIIa inhibitors or bivalirudin)
or different revascularization strategies (e.g., thrombectomy,
direct stenting) was left to the operators according to the
institution’s standard procedure. Unless clinically contrain-
dicated, all anticoagulants were discontinued at the end of
the procedure, whereas glycoprotein IIb/IIIa inhibitor bo-
luses were followed by a 12-h infusion. All patients were
pre-treated with acetylsalicylic acid plus a loading dose of
clopidogrel (300 to 600 mg) and were discharged on dual-
antiplatelet therapy for 12 months at the discretion of the
operator and depending on the stent implanted.
Before the procedure, bilateral femoral and radial pulses
were evaluated by a physician. In particular, Allen’s test was
performed twice on both hands to exclude insufficient ulnar
collateral circulation; in case of an abnormal Allen’s test
result, further evaluation with pulse oximetry or plethys-
mography was not precluded but not encouraged to prevent
consistent time delay. In patients presenting with cardio-
genic shock, radial pulse and Allen’s test were assessed after
intra-aortic balloon positioning or specific pharmacological
treatment (i.e., inotropic drug administration); patients with
persistent pulseless cardiogenic shock were excluded from
the study.
All participating interventional cardiologists were high-
volume operators (150 PCIs/year) and had adequate
expertise in both approaches, meeting minimal proficiency
criteria of 50% interventional cases by radial approach per
year.
Data collection and definitions. By design, ad hoc dedi-
cated databases for data entry and explicit definitions for
outcomes were adopted. Data on 30-day outcomes were
obtained by direct patient visit or contact with referring
physician in the absence of any adverse event. Source
documentation was obtained for all clinical events and
analyzed by the central clinical-event committee.
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cause, procedure-related deaths, and death of unknown
cause. Stroke was defined as the presence of a new focal
neurological deficit thought to be vascular in origin, with
sign or symptoms persisting 24 h and in the presence of
cerebral lesions as assessed by imaging procedures. New
myocardial infarction was defined as new ischemic symp-
toms lasting 20 min and new or recurrent ST-segment
elevation or depression 1 mm in at least 2 contiguous
leads, associated with a 20% increase of the cardiac
biomarker values not attributable to the evolution of the
index myocardial infarction (19). Target lesion revascular-
ization was defined as any revascularization procedure per-
formed because of angiographic restenosis or thrombosis
t the site of the culprit lesion, associated with clinical
nd/or objective evidence of inducible myocardial isch-
mia. Stent thrombosis was classified using the Academic
esearch Consortium definition (20). Post-procedural
leeding (Table 1) was considered to be any overt and
ctionable hemorrhage not related to coronary artery
ypass graft with 3 g/dl decrease in hemoglobin,
requiring prompt evaluation by a health care professional
and leading to an increased level of care. Bleeding was
further categorized as access site and non–access site
related according to its relationship to the arterial vascu-
lar access.
Statistical analysis. Assumptions for sample-size analysis
were based, for the control event rate, on NACE rates
reported in the HORIZONS-AMI (Harmonizing Out-
comes With Revascularization and Stents in Acute Myo-
cardial Infarction) trial and pertinent meta-analyses (21–23)
and, for the experimental event rate, on several meta-
analyses on radial access (11,22,23). It must be emphasized
that the concept of NACEs is a relatively novel one and that
its absolute rates are highly variable, depending on the
definitions of myocardial infarction, revascularization, and,
most importantly, bleeding. Thus, the consensus among
members of the steering committee was that assuming a
9.2% 30-day NACE rate in the control group and a 4.5%
rate in the experimental group could be clinically and
scientifically sound. Thus, aiming for 5% alpha and 20%
beta errors and discounting for a likely 5% rate of losses to
follow-up, 500 patients were included in each group (N 
1,000).
Bleeding DefinitionTable 1 Bleeding Definition
Overt and Actionable Bleeding Needing Evaluation by
Physician and Fulfilling the Following Criteria
Bleeding requiring blood transfusion Leading to:
Bleeding requiring surgical repair Unplanned diagnostic
examinations and/or
Cerebral bleeding  Prolonged hospitalization and/or
Intracranial or retroperitoneal bleeding Lifesaving drug discontinuation
Decrease in hemoglobin level 3 g/dl
Intrapericardial with cardiac tamponadeFatal bleedingBaseline characteristics of the patients are summarized
with mean  SD for continuous variables with normal
distribution, median (first to third quartiles) for those
continuous but with skewed distribution, and number (per-
centage) for categorical variables; 95% confidence intervals
(CIs) for proportions are calculated by the Wilson method.
The Student t, Mann-Whitney U, and Fisher exact tests
were computed when appropriate for bivariate analyses.
Combined adverse events were evaluated on a per-patient
hierarchical basis; thus, each patient could provide only 1
hard event per event type. Analyses were conducted on
intention-to-treat basis, regardless possible access site cross-
over or unneeded coronary revascularization. Cumulative
event rates were compared with the log-rank test and
summarized as Kaplan-Meier estimates.
All variables in Tables 2 and 3 were tested for bivariate
association with NACEs, and nominally significant (p 
0.05) covariates were simultaneously forced into a Cox
regression model to identify independent outcome predic-
tors and to calculate their adjusted hazard ratios (HRs) with
associated 95% CIs. A 2-tailed p value 0.05 was estab-
lished as the level of statistical significance for all tests. All
statistical analyses were performed using SPSS-PASW
version 18.0 (IBM, Armonk, New York).
Results
Baseline population characteristics. Between January
2009 and July 2011, 501 patients were randomly assigned to
femoral access and 500 to radial access (Fig. 1). The
enrollment rate was 75% of all STEACS patients treated
at the participating centers during the study period. There
were no significant baseline demographic and clinical dif-
ferences between the 2 study arms (Table 2). The prevalence
of comorbidities and severity of coronary artery disease were
comparable as well as acute clinical presentation with10%
of patients in Killip class III/IV and 8% requiring intra-
aortic balloon support during the procedure.
Procedural characteristics. There were no differences in
the symptom-to-balloon and door-to-balloon times be-
tween the 2 study groups (Table 3), whereas the time from
artery puncture to first balloon inflation was slightly longer
in the radial group (10 min [range, 8 to 20 min] vs. 10 min
[range, 8 to 15 min], p  0.035). A sheath 6-F was used
more frequently in the radial group than in the femoral
group (90.8% vs. 81.4%, p  0.001) (Table 3). The overall
rate of vascular approach crossover was 6.1% (n 61): 9.6%
(n 47) in the radial arm and 2.8% (n 14) in the femoral
arm. However, excluding cases of nonadherence to the
randomized allocation by operators (Fig. 1), the actual
access failure was 6% (n  30) in the radial arm and 1%
(n  5) in the femoral arm. Cardiogenic shock at presen-
tation (HR: 3.43; 95% CI: 1.7 to 7.1; p  0.01), unknown
peripheral vascular disease (HR: 2.55; 95% CI: 1.4 to 4.6;
p  0.02), and previous thrombolytic administration (HR:
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determinants of vascular access crossover.
Lesion and procedural characteristics for the 2 groups
were also well balanced (e.g., target vessel distribution) with
a culprit lesion clearly identifiable in 99% of cases (Table 3).
The culprit vessel was occluded at the time of the procedure
in 60% of patients; thrombectomy devices were used in 41%,
whereas a direct stenting strategy was possible in 28% of
patients. The angiographic successful result rate, no-reflow
incidence, creatine kinase-myocardial band peak, and stent/
patient ratio were also comparable (Table 3).
Notably, periprocedural anticoagulant and antithrom-
botic therapies were similar in the 2 groups: 8% of patients
had received previous fibrinolytic treatment, the mean
heparin dose administered was 76  21 U/kg, and glyco-
protein IIb/IIIa inhibitors were used in 69% of patients,
whereas bivalirudin was used in only 8%.
30-day outcome. No patient was lost at 30-day follow-up;
thus, all 1,001 patients were included in the final intention-
to-treat-analyses. The primary endpoint of 30-day NACEs
Baseline Patient CharacteristicsTable 2 Baseline Patient Characteristics
Overall
(N  1,001)
Clinical characteristics
Age, yrs 65 (55–76
Female 267 (26.7)
Body mass index, kg/m2 27.0 (25–30
Left ventricular ejection fraction 45.0 (40–50
CKD (GFR 60 ml/min/1.73 m2) 238 (23.8)
COPD 71 (7.1)
Peripheral arterial disease 143 (14.3)
Previous myocardial infarction, 141 (14.1)
Previous cerebrovascular accident 41 (4.1)
Previous revascularization 117 (11.7)
Previous PCI 105 (10.5)
Previous CABG 19 (1.9)
Cardiac risk factors
Hypertension 608 (60.7)
Hypercholesterolemia 417 (41.7)
Smoking 401 (40.1)
Family history of CAD 177 (17.7)
Diabetes 237 (23.7)
Severity of CAD (p  0.471)
No epicardial vessel disease 11 (1.1)
Isolated left main disease 2 (0.2)
Single-vessel disease 544 (54.3)
Double-vessel disease 285 (28.5)
Triple-vessel disease 159 (15.9)
Killip class presentation (p  0.164)
I 678 (67.7)
II 210 (21.0)
III 52 (5.2)
IV 61 (6.1)
Values are n (%) or median (quartiles).
CABG  coronary artery bypass graft; CAD  coronary artery disea
disease; GFR  glomerular filtration rate; PCI  percutaneous coronaoccurred in 173 patients (17.3%) and was significantly fewer 0in the radial arm compared with the femoral arm (13.6% vs.
21.0%, 95% CI: 2.7% to 12.0%; p  0.003) (Table 4). A
aplan-Meier curve of the incidence of 30-day NACEs is
hown in Figure 2. Analysis of individual NACE compo-
ents showed 72 deaths (7.2%) attributable to cardiac causes
Online Appendix 1) with a significantly lower incidence in
atients randomized to the radial approach compared with
he femoral approach (5.2% vs. 9.2%; 95% CI: 0.8% to
.3%; p  0.020); on the contrary, myocardial infarction
1.2% vs. 1.4%; 95% CI: 1.4% to 1.8%; p  1.000), target
esion revascularization (1.2% vs. 1.8%; 95% CI: 1.0% to
.3%; p  0.604), and stroke (0.8% vs. 0.6%; 95% CI:
1.5% to 1.0%; p  0.725) rates were comparable in the 2
study groups.
Bleeding occurred in 100 patients (10.0%) and was signifi-
cantly less frequent in the radial arm than in the femoral arm
(7.8% vs. 12.2%; 95% CI: 2.7% to 12.0%; p  0.026) (Table
4). This difference was mainly due to a 60% decrease in access
site–related bleeding in the radial group compared with the
femoral group (2.6% vs. 6.8%; 95% CI: 1.6% to 7.0%; p 
Femoral
(n  501)
Radial
(n  500) p Value
65 (55–77) 65 (56–75) 0.409
141 (28.1) 126 (25.2) 0.317
26.6 (24–30) 27.2 (25–30) 0.140
45.0 (40–50) 45.0 (40–52) 0.175
127 (25.3) 111 (22.2) 0.156
40 (8.0) 31 (6.2) 0.325
68 (13.6) 75 (15.0) 0.529
71 (14.2) 70 (14.0) 1.000
22 (4.4) 19 (3.8) 0.750
52 (10.4) 65 (13.0) 0.202
45 (9.0) 60 (12.0) 0.123
12 (2.4) 7 (1.4) 0.355
309 (61.7) 299 (59.8) 0.561
199 (39.7) 218 (43.6) 0.223
191 (38.1) 210 (42.0) 0.221
81 (16.2) 96 (19.2) 0.215
122 (24.4) 115 (23.0) 0.656
6 (1.2) 5 (1.0) 1.000
1 (0.2) 1 (0.2) 1.000
265 (52.9) 279 (55.8) 0.374
149 (29.7) 136 (27.2) 0.401
80 (16.0) 79 (15.8) 1.000
330 (65.9) 348 (69.6) 0.224
108 (21.5) 102 (20.4) 0.698
28 (5.6) 24 (4.8) 0.670
35 (7.0) 26 (5.2) 0.290
D  chronic kidney disease; COPD  chronic obstructive pulmonary
vention.)
)
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groups (5.2% vs. 5.4%; 95% CI: 2.7% to 3.0%; p  1.000).
he clinical relevance of this decrease in access site bleeding
as underscored by less need for blood transfusion in patients
ndergoing a transradial procedure (1.0% vs. 3.2%; 95% CI:
.4% to 4.2%; p 0.025). Post hoc bleeding analysis according
o the Thrombolysis In Myocardial Infarction classification
howed a comparable rate of major Thrombolysis In Myocar-
ial Infarction bleeding between the 2 groups (2.8% vs.
.8%; 95% CI: 0.9% to 3.0%; p  0.399), but a
ignificantly lower rate of minor Thrombolysis In Myo-
ardial Infarction bleeding in the radial arm (7.2% vs.
Lesion and Procedural CharacteristicsTable 3 Lesion and Procedural Characterist
Ove
(N  1
Target vessel
Left main trunk 6 (0.
Left anterior descending/diagonal artery 469 (46
Left circumflex/obtuse marginal artery 163 (16
Right coronary/posterior descending artery 342 (34
Bypass graft 10 (1.
Target lesion
Occlusive stenosis 597 (59
Stent thrombosis treatment 51 (5.
High thrombotic burden (TS 3) 782 (78
Bifurcation 184 (18
Procedural characteristics
Symptom-to-balloon time, min 207 (14
Door-to-balloon time, min 56 (34
Artery puncture-to-balloon time, min 10 (8–
Systolic blood pressure, mm Hg 129 (11
Arterial sheath size
6-F 862 (86
7-F 139 (13
Baseline TIMI flow grade 0.80
0–1 719 (71
2–3 282 (28
Baseline creatinine, mg/dl 0.94 (0.
Baseline hemoglobin, g/dl 14.3 (13
Stent/patient ratio 1.42
Total stent length, mm 24 (18
Drug-eluting stent implantation 243 (24
Failed thrombolysis 76 (7.
Heparin, U/kg 71 (62
Glycoprotein IIb/IIIa inhibitors 687 (68
Bivalirudin 76 (7.
Thrombectomy device use 407 (40
Direct stenting 281 (28
IABP support 80 (8.
CK-MB baseline, ng/ml 5.1 (3–
Final TIMI flow grade 2.82
0–1 37 (3.
2–3 964 (96
Angiographic failure* 121 (12
Values are n (%), median (quartiles), or mean  SD. *Angiographic fa
CK-MB creatine kinase-myocardial band; IABP intra-aortic ballo.0%; 95% CI: 0.3% to 6.1%; p  0.038) (Table 4). wHospital stay was shorter in the radial group than in the
emoral group (Table 4). Indeed, a significant reduction in
oronary care unit stay (3 days [range, 2 to 4 days] vs. 4 days
range, 3 to 5] days, p 0.001) after a transradial procedure led
o earlier discharge than after a transfemoral procedure (5 days
range, 4 to 7 days] vs. 6 days [range, 5 to 8 days], p 0.008).
he differences in terms of outcome between the 2 study
roups became more evident when data were analyzed accord-
ng to a per-protocol basis (Online Appendix 2).
utcome predictors. Multivariate analysis confirmed the
adial approach as an independent predictor of 30-day
ACEs (HR: 0.7; 95% CI: 0.5 to 0.9; p  0.028) together
Femoral
(n  501)
Radial
(n  500) p Value
4 (0.8) 2 (0.4) 0.687
234 (46.7) 235 (47.0) 0.950
75 (15.0) 88 (17.6) 0.267
177 (35.3) 165 (33.0) 0.464
5 (1.0) 5 (1.0) 1.000
299 (59.7) 298 (59.6) 1.000
21 (4.2) 30 (6.0) 0.200
394 (78.6) 388 (77.6) 0.703
85 (17.0) 99 (19.8) 0.254
) 198 (135–392) 214 (145–375) 0.290
53 (31–91) 60 (35–99) 0.175
10 (8–15) 10 (8–20) 0.035
) 123 (106–146) 130 (110–143) 0.104
408 (81.4) 454 (90.8) 0.001
93 (18.6) 46 (9.2) 0.001
0.76 1.0 0.83 1.1 0.309
367 (73.3) 352 (70.4) 0.326
134 (26.7) 148 (29.6) 0.326
0.95 (0.8–1.2) 0.93 (0.8–1.1) 0.112
14.2 (13–15) 14.3 (13–15) 0.153
1.41 0.9 1.43 1.0 0.745
24 (18–38) 24 (18–40) 0.265
111 (22.2) 132 (26.4) 0.122
35 (7.0) 41 (8.2) 0.477
70 (63–86) 71 (61–88) 0.973
350 (69.9) 337 (67.4) 0.414
36 (7.2) 40 (8.0) 0.635
203 (40.5) 204 (40.8) 0.949
140 (27.9) 141 (28.2) 0.944
42 (8.4) 38 (7.6) 0.727
5.2 (3–19) 5.1 (3–18) 0.112
2.81 0.6 2.83 0.6 0.657
19 (3.8) 18 (3.6) 1.000
482 (96.2) 482 (96.4) 1.000
65 (13.0) 56 (11.2) 0.438
TIMI flow grade 3 and/or residual stenosis 30%.
p; TIMI Thrombolysis In Myocardial Infarction; TS thrombus score.ics
rall
,001)
6)
.9)
.3)
.2)
0)
.6)
1)
.1)
.4)
0–380
–95)
17)
0–145
.1)
.9)
1.1
.8)
.2)
8–1.1)
–15)
0.9
–38)
.3)
6)
–87)
.6)
6)
.7)
.1)
0)
18)
0.56
7)
.3)
.1)ith female sex (HR: 1.4; 95% CI: 1.1 to 2.0; p  0.037),
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The RIFLE-STEACS Study December 18, 2012:2481–9chronic kidney disease (HR: 1.8; 95% CI: 1.3 to 2.5; p 
0.001), left descending artery as the culprit vessel (HR: 1.5;
95% CI: 1.1 to 2.0; p  0.020), Killip class at presentation
(HR: 1.5; 95% CI: 1.3 to 1.8; p  0.001), impaired left
ventricular ejection fraction (HR: 1.6; 95% CI: 1.1 to 2.3;
p  0.027), and angiographic no reflow (HR: 1.9; 95% CI:
1.3 to 2.7; p  0.001).
Discussion
The present multicenter randomized clinical trial has the
following implications. First, systematic use of transradial
access for STEACS treatment translates into an evident
clinical advantage in terms of NACEs, cardiac mortality,
and bleeding; second, the radial approach in these pa-
tients is associated with a substantial decrease in access
site hemorrhagic events compared with the femoral
approach; third, patients undergoing a transradial proce-
dure need shorter intensive coronary care unit and hos-
pital stays.
Hemorrhagic complications constitute an important risk
factor for a worse outcome in STEACS (1–3). Due to the
strict correlation among bleeding, ischemic events, and
mortality, more attention has been recently paid to the
reduction of all avoidable iatrogenic hemorrhagic complica-
tions. Several bleeding risk score models have been devel-
oped to define the patient risk profile and facilitate a
personalized decision-making process (24–26), but the
urgency of care and the unavoidable need to minimize
ischemic risk often limit the applicability of standardized
Figure 1 Study Flowchart
Flowchart of patients with ST-segment elevation acute coronary syndrome (STEACStreatment, especially in terms of antithrombotic regimens.In this context, use of the transradial approach for acute
patients undergoing early invasive treatment has undoubt-
edly a key role in the prevention of access site–related
bleeding, accounting for as many as 40% of all causes of
bleeding in acute coronary syndrome patients (1,2,6,27).
Several studies have strongly emphasized the possible link
between the decrease in major vascular complications and
improved outcome associated with the transradial approach,
especially in patients with STEACS (18,28). Nonetheless,
the currently available evidence in this context is limited by
the small number of patients and/or the observational study
design. More recently, the RIVAL study (18) and a post-
hoc analysis of the HORIZON-AMI trial showing im-
proved event-free survival in patients undergoing primary
PCI by the transradial approach (28) raised the question
about the best vascular access in acute patients.
The RIFLE-STEACS is the first large randomized
clinical trial specifically designed to compare the radial and
femoral approaches for primary/rescue PCI. The RIFLE-
STEACS is also the first randomized study to demonstrate
an improved outcome in terms of NACEs and cardiac
survival associated with the radial approach in patients with
STEACS. This result is consistent with data emerging from
meta-analyses and pooled analyses demonstrating in
STEMI patients a 46% to 48% reduction in risk of mortality
associated with the transradial approach compared with
transfemoral access (23,29). The 30-day rate of 7.2% of
cardiac deaths seen in this trial is higher than the rate of
2.9% reported in the heparin plus glycoprotein IIb/IIIa
lled in the study.) enroinhibitors group in HORIZON-AMI trial (21); neverthe-
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December 18, 2012:2481–9 The RIFLE-STEACS Studyless, the less stringent selection criteria and the inclusion of
patients with critical conditions such as cardiogenic shock
and failed thrombolysis may explain this significant differ-
ence in cardiac mortality (23,29).
Possible explanations for this beneficial effect on outcome
seem to be the lower rate of bleeding-related hemodynamic
compromise, need for blood transfusion, and lifesaving drug
discontinuation. Indeed, in this nearly all-comers study,
radial access reduced the odds of clinically relevant access
site bleeding by 60%, with a significant decrease in the need
for transfusion. These data are consistent with the results of
previous reports showing as much as a 55% reduction in the
rate of non–coronary artery bypass graft–related bleeding
(23,28). To overcome the evident limit of the heterogeneous
bleeding classifications adopted in previous studies (30) and
to focus only on hemorrhagic complications potentially
affecting the outcome (31,32), the RIFLE-STEACS con-
sidered only overt bleeding events causing substantial blood
loss and requiring increased level of care (e.g., unplanned
diagnostic exam) and/or specific treatment (e.g. antithrom-
botic therapy modification); thus, ordinary access site local
hematomas independently from its dimensions were not
In-Hospital and Follow-Up Clinical OutcomesTable 4 In-Hospital and Follow-Up Clinical O
O
(N 
30-day outcome (hierarchical)
NACE 173
MACE 93
Cardiac death 72
Stroke 7
Myocardial infarction 13
Target lesion revascularization 15
Stent thrombosis 15
Definite 12
Probable 1
Possible 2
Non-CABG bleeding 100
Access site related 47
Non–access site related 53
TIMI major bleeding 23
TIMI minor bleeding 56
TIMI bleeding requiring medical attention 21
Blood transfusion required 21
Surgical repair required 3
Cerebral bleeding 1
Intracranial or retroperitoneal bleeding 2
Decrease in hemoglobin level 3 g/dl 79
Intrapericardial with cardiac tamponade 5
Fatal bleeding 6
Hospital stay, days (range)
Total hospital stay 6
Intensive coronary care unit 3
Cardiology ward 3
Values are n (%) and median (quartiles).
MACE hierarchical major adverse cardiac event (cardiac death, no
net adverse clinical event (MACE  bleeding); other abbreviations asconsidered for the primary outcome. Again, the high patient urisk profile and the extensive use of glycoprotein IIb/IIIa
inhibitors (32), might partially explain the considerable
hemorrhagic event rate recorded in this study population.
Nonetheless, considering the inclusion of patients with
failed thrombolysis (i.e., rescue PCI) and the low use of
bivalirudin in the RIFLE-STEACS, the 10% bleeding rate
at 30 days is to some extent comparable to the 7.3% reported
in the post-hoc analysis of the HORIZON-AMI study
(28). Notably, non–access site–related bleeding still ac-
counted for 50% of all hemorrhagic events, underscoring
he fact that the choice of the best antithrombotic regimen
ith the lowest bleeding potential remains a major issue to
ncrease the safety margin in the treatment of patients with
TEACS.
Thus, the reduction in cardiac mortality and bleeding
ound in the radial arm of the RIFLE-STEACS corrobo-
ates the link between mortality and “clinically relevant”
ccess site bleeding (33,34). The multivariable analysis
onfirmed the role of a systematic radial approach as an
ndependent 30-day outcome predictor.
Consistent with an improved clinical outcome, patients in
he radial arm also showed a shorter intensive coronary care
es
1)
Femoral
(n  501)
Radial
(n  500) p Value
) 105 (21.0) 68 (13.6) 0.003
57 (11.4) 36 (7.2) 0.029
46 (9.2) 26 (5.2) 0.020
3 (0.6) 4 (0.8) 0.725
7 (1.4) 6 (1.2) 1.000
9 (1.8) 6 (1.2) 0.604
9 (1.8) 6 (1.2) 0.604
7 (1.4) 5 (1.0) 0.773
1 (0.2) 0 (0.0) 1.000
1 (0.2) 1 (0.2) 1.000
) 61 (12.2) 39 (7.8) 0.026
34 (6.8) 13 (2.6) 0.002
27 (5.4) 26 (5.2) 1.000
14 (2.8) 9 (1.8) 0.399
36 (7.2) 20 (4.0) 0.038
11 (2.2) 10 (2.0) 0.502
16 (3.2) 5 (1.0) 0.025
2 (0.4) 1 (0.2) 0.999
0 (0.0) 1 (0.2) 0.999
1 (0.2) 1 (0.2) 0.480
49 (9.8) 30 (6.0) 0.036
3 (0.6) 2 (0.4) 0.998
3 (0.6) 3 (0.6) 0.684
) 6 (5–8) 5 (4–7) 0.008
) 4 (3–5) 3 (2–4) 0.001
) 3 (1–4) 2 (1–4) 0.472
yocardial infarction, target lesion revascularization, stroke); NACE
s 2 and 3.utcom
verall
1,00
(17.3
(9.3)
(7.2)
(0.7)
(1.3)
(1.5)
(1.5)
(1.2)
(0.1)
(0.2)
(10.0
(4.7)
(5.3)
(2.3)
(5.6)
(2.1)
(2.1)
(0.3)
(0.1)
(0.2)
(7.9)
(0.5)
(0.3)
(5–8
(2–4
(1–4nit stay, translating into reduced overall hospital stay.
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The RIFLE-STEACS Study December 18, 2012:2481–9Because prolonged bed rest itself seems to be a predictor of
worse prognosis in coronary artery disease (35), the possi-
bility of a more rapid mobilization as a result of the decrease
in access site complications might have also played a role in
the outcome difference.
Finally, the few exclusion criteria adopted in this trial and
the enrollment of quite complex patients together with
subjects at lower risk also confirm the feasibility of the radial
approach in the emergency setting, with an access failure
rate of 6% and negligible time delay by expert operators.
This access crossover rate is comparable to the 5.3% rate
reported in the RIVAL study (18) and the 3.8% rate
reported by expert operators choosing the radial approach as
initial access for primary PCI in patients without cardio-
genic shock (36). Nonetheless, specific transradial expertise
to guarantee procedural time and a success rate comparable
to those with the femoral approach are strongly recom-
mended before using this technique in the emergency
setting. The exclusion of those who are not ideal candidates
for radial approach (e.g., abnormal Allen’s test) and the
ability to handle specific vascular access difficulties (e.g.,
unfavorable anatomic variants) are necessary to avoid harm-
ful treatment delays in treating STEACS patients (37,38).
Indeed, there is some evidence that the more expert the
operator is with radial access, the more patients will benefit
from the use of radial approach (36,39).
Study limitations. The main limitation of this study is the
almost exclusive use of heparin and glycoprotein IIb/IIIa
inhibitors, with only 8% of patients receiving bivalirudin.
Although it could have negatively affected the rate of
Figure 2 Time-to-Event Curves for NACE
Net adverse cardiac event (NACE) is the composite of cardiac death,
myocardial infarction, target lesion revascularization, stroke, and bleeding.bleeding events recorded in the study, the post hoc analysisof the HORIZON-AMI confirmed the advantage of the
transradial approach with regard to hemorrhagic complica-
tions also in patients treated with bivalirudin (28). This may
also explain the relatively high rate of NACEs in the
femoral group in our trial compared with other similar
randomized studies.
A second limitation is the fact that all operators were
skilled in the radial approach thus making the external
validity of these results lower for centers where operators
mainly perform transfemoral procedures, underscoring the
need for suitable training and learning curve for the radial
approach to achieve optimal clinical results.
Another limitation is the sample size computation, which
was based on analysis of published data as well as consensus
among steering committee members, because the concept of
NACEs is a new one in the field of STEACS, and NACE
rates vary substantially depending on definitions.
Finally, notwithstanding the comparable baseline clinical
and procedural characteristics as well as in-hospital man-
agement and complication rates between the 2 study groups,
the possible role of unknown confounding factors on out-
come could not be excluded. Indeed, most cardiac deaths
were recorded in the early acute phase of STEACS (within
48 h), making the role of bleeding in the outcome not
always clearly assessable (Online Appendix 1). Thus, further
studies to confirm the benefit of the radial approach on
survival in STEACS patients are warranted.
Conclusions
The RIFLE-STEACS results clearly demonstrate the ad-
vantage in terms of outcome of the radial over the femoral
approach in STEACS patients. This net difference together
with the high success rate should represent the primary
reason to use the radial approach for the treatment of acute
patients.
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